JP2008522162A5 - - Google Patents

Download PDF

Info

Publication number
JP2008522162A5
JP2008522162A5 JP2007543518A JP2007543518A JP2008522162A5 JP 2008522162 A5 JP2008522162 A5 JP 2008522162A5 JP 2007543518 A JP2007543518 A JP 2007543518A JP 2007543518 A JP2007543518 A JP 2007543518A JP 2008522162 A5 JP2008522162 A5 JP 2008522162A5
Authority
JP
Japan
Prior art keywords
mer
molecular weight
tyrosine kinase
receptor tyrosine
transmembrane receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007543518A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008522162A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/042724 external-priority patent/WO2006058202A2/en
Publication of JP2008522162A publication Critical patent/JP2008522162A/ja
Publication of JP2008522162A5 publication Critical patent/JP2008522162A5/ja
Pending legal-status Critical Current

Links

JP2007543518A 2004-11-24 2005-11-23 Merの診断用および治療用の作用薬 Pending JP2008522162A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63019204P 2004-11-24 2004-11-24
PCT/US2005/042724 WO2006058202A2 (en) 2004-11-24 2005-11-23 Mer diagnostic and therapeutic agents

Publications (2)

Publication Number Publication Date
JP2008522162A JP2008522162A (ja) 2008-06-26
JP2008522162A5 true JP2008522162A5 (https=) 2009-01-15

Family

ID=36498546

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007543518A Pending JP2008522162A (ja) 2004-11-24 2005-11-23 Merの診断用および治療用の作用薬

Country Status (5)

Country Link
US (2) US20080267975A1 (https=)
EP (1) EP1825005B1 (https=)
JP (1) JP2008522162A (https=)
CA (1) CA2630475A1 (https=)
WO (1) WO2006058202A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2555763A1 (en) * 2004-01-29 2005-08-11 Asahi Kasei Pharma Corporation Therapeutic agent for vasospasm accompanying bypass operation
WO2008098139A2 (en) 2007-02-07 2008-08-14 The Regents Of The University Of Colorado Axl tyrosine kinase inhibitors and methods of making and using the same
CA2786149C (en) * 2010-01-22 2019-11-12 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl signaling in anti-metastatic therapy
WO2012149018A1 (en) * 2011-04-25 2012-11-01 The Regents Of The University Of Colorado Mer tyrosine kinase inhibitors and methods of making and using the same
WO2013090776A1 (en) 2011-12-15 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl/gas6 signaling in the treatment of disease
PT3326622T (pt) 2012-12-14 2021-04-07 Univ Leland Stanford Junior Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática
KR20150040766A (ko) * 2013-10-07 2015-04-15 이화여자대학교 산학협력단 항염증 물질을 스크리닝하는 방법
US10137173B2 (en) 2014-10-20 2018-11-27 Aravive Biologics, Inc. Antiviral activity of Gas6 inhibitor
JP7211703B2 (ja) 2014-12-22 2023-01-24 ザ ロックフェラー ユニバーシティー 抗mertkアゴニスト抗体及びその使用
JP2020526584A (ja) 2017-06-28 2020-08-31 ザ ロックフェラー ユニバーシティー 抗mertkアゴニスト抗体−薬物コンジュゲートおよびその使用
JP2023506465A (ja) 2019-12-13 2023-02-16 アレクトル エルエルシー 抗MerTK抗体及びその使用方法
CN111812014B (zh) * 2020-08-05 2023-04-18 上海市血液中心 一种基于纳米材料的血小板抗体检测方法和血小板保存方法
CA3217372A1 (en) * 2021-05-14 2022-11-17 Masoud TAVAZOIE Mertk peptides and uses thereof
JP2024527493A (ja) 2021-06-16 2024-07-25 アレクトル エルエルシー 一価の抗MerTK抗体及びその使用方法
US20240279341A1 (en) 2021-06-16 2024-08-22 Alector Llc Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5585269A (en) * 1994-06-02 1996-12-17 The University Of North Carolina At Chapel Hill Isolated DNA encoding c-mer protooncogene
US20030166132A1 (en) * 1998-08-26 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030144237A1 (en) * 2000-04-13 2003-07-31 Peter Carmeliet Use of inhibition of a gas6 function or of a gas6 receptor for preventing and treating a cardiovascular disease
US20040018513A1 (en) * 2002-03-22 2004-01-29 Downing James R Classification and prognosis prediction of acute lymphoblastic leukemia by gene expression profiling
AU2003276958A1 (en) * 2002-09-24 2004-04-19 Centocor, Inc. Epitope-tagged recombinant growth arrest specific gene 6 protein

Similar Documents

Publication Publication Date Title
JP2008522162A5 (https=)
Landoni et al. Modifications to the framework regions eliminate chimeric antigen receptor tonic signaling
JP2022104941A (ja) ヒト化抗cd73抗体
Roth et al. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis
Wright et al. The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans
TW438809B (en) Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
Kamihira et al. Aberrant expression of caspase cascade regulatory genes in adult T‐cell leukaemia: survivin is an important determinant for prognosis
Shisler et al. The adenovirus E3-10.4 K/14.5 K complex mediates loss of cell surface Fas (CD95) and resistance to Fas-induced apoptosis
Williams et al. Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis
CN103459595B (zh) 针对人前列腺素e2受体ep4的抗体
KR20200020662A (ko) 면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
PT98394B (pt) Processo para a preparacao de formas multimericas da proteina receptora de rinovirus humano
CN111148514A (zh) 与免疫调节剂联合应用于癌症免疫治疗的rar选择性激动剂
JP2013520171A (ja) Wntシグナル伝達経路を阻害するモノクローナル抗体ならびにその製造方法およびその使用方法
KR20140054238A (ko) 인테그린 알파-v 베타-8에 결합하는 항체
CN109563154B (zh) 抗帕多瓦因子ix抗体
US11911404B2 (en) Fucosylation and immune surveillance in melanoma
Yard et al. Decreased glomerular expression of agrin in diabetic nephropathy and podocytes, cultured in high glucose medium
Horváth et al. IgA autoantibodies in the pemphigoids and linear IgA bullous dermatosis
PT1079843E (pt) Utilização dos inibidores do receptor de integrina 1 1 e dos inibidores de fct- 1 no tratamento de doenças do rim
KR20240112996A (ko) Hpv16 e7 항원을 인식하는 결합 단백질 및 이의 용도
JP2010525795A (ja) オステオポンチンの機能エピトープ、それと特異的に結合するモノクローナル抗体およびその抗腫瘍薬の製造のための用途
Chang Molecular mechanism of ATP-dependent solute transport by multidrug resistance-associated protein 1
Craig et al. Failure to block adhesion of Plasmodium falciparum-infected erythrocytes to ICAM-1 with soluble ICAM-1
Pinkert et al. The coxsackievirus and adenovirus receptor: glycosylation and the extracellular D2 domain are not required for coxsackievirus B3 infection